Aleksandra Rizo

Executive Vice President & Chief Medical Officer at Geron Corp.

Aleksandra Rizo

Aleksandra Rizo

Executive Vice President & Chief Medical Officer at Geron Corp.

Overview
Career Highlights

Celgene Corp.

RelSci Relationships

4026

Number of Boards

1

Birthday

1975

Age

44

Relationships
RelSci Relationships are individuals Aleksandra Rizo likely has professional access to. A relationship does not necessarily indicate a personal connection.

Member, Executive Committee & Chief Scientific Officer at Johnson & Johnson

Relationship likelihood: Strong

Chairman of the Board, President & Chief Executive Officer at Geron Corp.

Relationship likelihood: Strong

Company Group Chairman, North America Pharmaceuticals at Johnson & Johnson

Relationship likelihood: Strong

Head of Human Resources, Global Pharmaceuticals Group & External Innovation at Johnson & Johnson

Relationship likelihood: Strong

Former Executive Director & Medical Affairs at Geron Corp.

Relationship likelihood: Strong

Head-Oncology Therapeutic Area at Janssen Research & Development LLC

Relationship likelihood: Strong

Chief Biotechnology Officer at Janssen Research & Development LLC

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Ci:z Holdings Co., Ltd.

Relationship likelihood: Strong

Vice Chairman at Johnson & Johnson

Relationship likelihood: Strong

Global Lead, Pharmaceuticals Communication & Public Affairs at Johnson & Johnson

Relationship likelihood: Strong

Paths to Aleksandra Rizo
Potential Connections via
Relationship Science
You
Aleksandra Rizo
Executive Vice President & Chief Medical Officer at Geron Corp.
Education

The University of Tokyo was established in 1877 as the first national university in Japan. As a leading research university, UTokyo offers courses in essentially all academic disciplines at both undergraduate and graduate levels and conducts research across the full spectrum of academic activity. The University aims to provide its students with a rich and varied academic environment that ensures opportunities for both intellectual development and the acquisition of professional knowledge and skills. To learn more about the University of Tokyo, please visit the pages below.

Rijksuniversiteit Groningen

Ss. Cyril and Methodius University of Skopje is a school in Skopje.

Career History
Executive Vice President & Chief Medical Officer
2019 - Current

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Clinical Leader
Tenure Unconfirmed

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Executive Director-Strategy
2018 - 2019

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Aleksandra Rizo. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Aleksandra Rizo's profile does not indicate a business or promotional relationship of any kind between RelSci and Aleksandra Rizo.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/aleksandra-rizo-226907466
  • https://relationshipscience.com/person/aleksandra-rizo-226907466